Form 4 for TRVI Trevi Therapeutics, Inc.
Accepted 2024-05-24 00:00:00 ET · period of report 2024-05-22 · accession 0000950170-24-064598 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-05-24 | 2024-05-22 | TRVI | Delfini Lisa | CFO | M - OptEx | $0.51 | +16.0K | 57.6K | +39% | +$8,182 |
| D | 2024-05-24 | 2024-05-22 | TRVI | Delfini Lisa | CFO | S - Sale+OE | $2.64 | -4,350 | 53.3K | -8% | -$11.5K |
| D | 2024-05-24 | 2024-05-22 | TRVI | Delfini Lisa | CFO | M - OptEx | $0.00 | -16.0K | 48.1K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-22 | M | A | 16,043 | $0.51 | 57,629 | D | — | — | (F1) Includes 5,685 shares purchased through the Issuer's employee stock purchase plan. |
| 2 | Common | Common Stock | 2024-05-22 | S | D | 4,350 | $2.64 | 53,279 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.64 to $2.65 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. (F1) Includes 5,685 shares purchased through the Issuer's employee stock purchase plan. |
| 3 | Derivative | Stock Option (right to buy) | 2024-05-22 | M | D | 16,043 | $0.00 | 48,125 | D | $0.51 · — to 2032-02-10 | 16,043 Common Stock | (F4) This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026. |